PURPOSE: The International Peripheral T-Cell Lymphoma Project was undertaken to better understand the subtypes of T-cell and natural killer (NK) -cell lymphomas. PATIENTS AND METHODS: Angioimmunoblastic T-cell lymphoma (AITL) was diagnosed according to the 2001 WHO criteria by a central review process consisting of panels of expert hematopathologists. Clinical, pathologic, immunophenotyping, treatment, and survival data were correlated. RESULTS: Of 1,314 patients, 243 (18.5%) were diagnosed with AITL. At presentation, generalized lymphadenopathy was noted in 76% of patients, and 89% had stages III to IV disease. Skin rash was observed in 21% of patients. Hemolytic anemia and hypergammoglobulinemia occurred in 13% and 30% of patients, respectively. Five-year overall and failure-free survivals were 33% and 18%, respectively. At presentation, prognostic models were evaluated, including the standard International Prognostic Index, which comprised the following factors: age ≥ 60 years, stages III to IV disease, lactic dehydrogenase (LDH) > normal, extranodal sites (ENSs) > one, and performance status (PS) ≥ 2; the Prognostic Index for Peripheral T-Cell Lymphoma, comprising: age ≥ 60 years, PS ≥ 2, LDH > normal, and bone marrow involvement; and the alternative Prognostic Index for AITL (PIAI), comprising: age > 60 years, PS ≥ 2, ENSs > one, B symptoms, and platelet count < 150 × 10(9)/L. The simplified PIAI had a low-risk group (zero to one factors), with 5-year survival of 44%, and a high-risk group (two to five factors), with 5-year survival of 24% (P = .0065). CONCLUSION: AITL is a rare clinicopathologic entity characterized by an aggressive course and dismal outcome with current therapies.
PURPOSE: The International Peripheral T-Cell Lymphoma Project was undertaken to better understand the subtypes of T-cell and natural killer (NK) -cell lymphomas. PATIENTS AND METHODS: Angioimmunoblastic T-cell lymphoma (AITL) was diagnosed according to the 2001 WHO criteria by a central review process consisting of panels of expert hematopathologists. Clinical, pathologic, immunophenotyping, treatment, and survival data were correlated. RESULTS: Of 1,314 patients, 243 (18.5%) were diagnosed with AITL. At presentation, generalized lymphadenopathy was noted in 76% of patients, and 89% had stages III to IV disease. Skin rash was observed in 21% of patients. Hemolytic anemia and hypergammoglobulinemia occurred in 13% and 30% of patients, respectively. Five-year overall and failure-free survivals were 33% and 18%, respectively. At presentation, prognostic models were evaluated, including the standard International Prognostic Index, which comprised the following factors: age ≥ 60 years, stages III to IV disease, lactic dehydrogenase (LDH) > normal, extranodal sites (ENSs) > one, and performance status (PS) ≥ 2; the Prognostic Index for Peripheral T-Cell Lymphoma, comprising: age ≥ 60 years, PS ≥ 2, LDH > normal, and bone marrow involvement; and the alternative Prognostic Index for AITL (PIAI), comprising: age > 60 years, PS ≥ 2, ENSs > one, B symptoms, and platelet count < 150 × 10(9)/L. The simplified PIAI had a low-risk group (zero to one factors), with 5-year survival of 44%, and a high-risk group (two to five factors), with 5-year survival of 24% (P = .0065). CONCLUSION: AITL is a rare clinicopathologic entity characterized by an aggressive course and dismal outcome with current therapies.
Authors: Owen A O'Connor; Steven Horwitz; Paul Hamlin; Carol Portlock; Craig H Moskowitz; Debra Sarasohn; Ellen Neylon; Jill Mastrella; Rachel Hamelers; Barbara Macgregor-Cortelli; Molly Patterson; Venkatraman E Seshan; Frank Sirotnak; Martin Fleisher; Diane R Mould; Mike Saunders; Andrew D Zelenetz Journal: J Clin Oncol Date: 2009-08-03 Impact factor: 44.544
Authors: Benjamin Kaffenberger; Brad Haverkos; Kelly Tyler; Henry K Wong; Pierluigi Porcu; Alejandro Ariel Gru Journal: Am J Dermatopathol Date: 2015-08 Impact factor: 1.533
Authors: Oreofe Odejide; Oliver Weigert; Andrew A Lane; Dan Toscano; Matthew A Lunning; Nadja Kopp; Sunhee Kim; Diederik van Bodegom; Sudha Bolla; Jonathan H Schatz; Julie Teruya-Feldstein; Ephraim Hochberg; Abner Louissaint; David Dorfman; Kristen Stevenson; Scott J Rodig; Pier Paolo Piccaluga; Eric Jacobsen; Stefano A Pileri; Nancy L Harris; Simone Ferrero; Giorgio Inghirami; Steven M Horwitz; David M Weinstock Journal: Blood Date: 2013-12-17 Impact factor: 22.113
Authors: Jose R Cortes; Alberto Ambesi-Impiombato; Lucile Couronné; S Aidan Quinn; Christine S Kim; Ana C da Silva Almeida; Zachary West; Laura Belver; Marta Sanchez Martin; Laurianne Scourzic; Govind Bhagat; Olivier A Bernard; Adolfo A Ferrando; Teresa Palomero Journal: Cancer Cell Date: 2018-02-02 Impact factor: 31.743
Authors: Bradley M Haverkos; Ying Huang; Alejandro Gru; Preeti Pancholi; Aharon G Freud; Anjali Mishra; Amy S Ruppert; Robert A Baiocchi; Pierluigi Porcu Journal: Int J Cancer Date: 2017-04-15 Impact factor: 7.396